-
Attribution:
-
Druker BJ Imatinib (Gleevec) as a Paradigm of
Targeted Cancer Therapeies (Part I:
Imatinib (Gleevec: A Targeted Cancer
Therapy) https://www.youtube.com/watch?v=d6xU3bgBLIw
March 29, 2010
-
"Imatinib
(Gleevec) has become a paradigm for targeted
cancer therapies.
-
"The first part of this lecture
will describe the clinical features and the
molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia
(CML).
-
"This overview will trace the history of
the identification of the target of imatinib,
BCR-ABL.
-
"The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly
successful clinical trials of this agent for
patients with CML will be reviewed along with
the most up-to-date follow-up on these studies."17
-
iBiology Youtube
Channel:
https://www.youtube.com/channel/UCsvqEZBO-kNmwuDBbKbfL6A
|
